Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com -- Bayer (OTC:BAYRY), the German pharmaceutical and agricultural supplies manufacturer, announced on Tuesday its plans to launch two new drugs this year. These drugs, which have the potential to generate at least $1 billion each in peak annual sales, are part of Bayer’s strategy to bolster its pharmaceuticals business while dealing with significant debt.
The first drug, Beyonttra, also known as acoramidis, is intended to treat a condition that leads to heart failure. The second drug, elinzanetant, is set to be launched in late summer and is aimed at providing relief from hot flashes experienced during menopause.
Bayer described both drugs as having "blockbuster potential," a term used in the industry to denote drugs that can potentially achieve peak annual sales of at least $1 billion. These upcoming launches demonstrate Bayer’s commitment to strengthening its pharmaceuticals business in the face of high debt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.